Platelet GP IIb/IIIa Receptor Inhibition by Eptifibatide in non ST-elevation MI-Acute Coronary Syndrome

S  Abdi; M  Momtahen; F  Javadzadeh; BF  Farsad; AS  Kazzazi; ,  Sharifian; S  Momtahen

International Cardiovascular Research Journal

The Official Annually Journal of Cardiovascular Research Center, Shiraz University of Medical Sciences

Current Issue All Issues In Press Accepted Manuscripts Search

Journal Information Boards & Committees Indexing and Listing Sources Journal Metrics Publication Ethics and Publication Malpractice Statement Contact Us Support Reviewer and AE Registration Form

APC

Authors Guide Submit Manuscript

Platelet GP IIb/IIIa Receptor Inhibition by Eptifibatide in non ST-elevation MI-Acute Coronary Syndrome

Authors:

S Abdi¹,

M Momtahen^1,*,

F Javadzadeh¹,

BF Farsad¹,

AS Kazzazi¹,

, Sharifian¹,

S Momtahen¹

1Department of Echocardiography, Shaheed Rajaei Cardiovascular Medical and Research Center, Tehran, Iran

International Cardiovascular Research Journal:Vol. 3, issue 2; e68402

Published online:Jun 30, 2009

Article type:Research Article

Received:Mar 10, 2018

Accepted:Jun 30, 2009

How to Cite:S AbdiM MomtahenF JavadzadehBF FarsadAS Kazzazi, SharifianS Momtahenet al.Platelet GP IIb/IIIa Receptor Inhibition by Eptifibatide in non ST-elevation MI-Acute Coronary Syndrome.3(2):e68402.

Abstract

Background: Recent trials of platelet glycoprotein IIb/IIIa receptor inhibitors have improved our understanding
to best use these powerful antiplatelet drugs in acute coronary syndrome. We tested the hypothesis that inhibition
of GPIIb/IIIa platelet receptor with Eptifibatide is effective as an empiric therapy in patients with acute coronary
syndrome who do not necessarily undergo immediate revascularization.
Methods: Since Feb 2006 one hundred and ninety-six patients who had presented with non ST-elevation acute
coronary syndrome (NSTE-ACS) were randomly assigned to receive Eptifibatide in addition to standard therapy,
for up to 72 hours or routine standard therapy. The primary end point was composite of death and non-fatal
myocardial infarction (MI) or urgent target vessel revascularization (TVR) in 30 days.
Results: The incidence of composite end point of death, non fatal MI and urgent TVR was significantly lower in
Eptifibatide group than standard group (16% vs. 0% - P value <0.01),particularly in troponin positive subgroup
of patients (27.8% vs. 0% - P value <0.01).
Any major adverse reaction such as major bleeding, stroke, or thrombocytopenia was not seen.
Conclusion: Early administration of GP IIb/IIIa receptor inhibitor is recommended in patients with high-risk
acute coronary syndrome.

Keywords

GP IIb/IIIa Receptor Inhibitor

Eptifibatide

Acute Coronary Syndrome

Fulltext

The full text is available in PDF.

References

1.
The references are available in PDF.

comments